Kang Stem Biotech Co., Ltd. announced that it has received KRW 30 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, LIG Investment & Securities Co., Ltd., Investment Arm, and other investors
September 07, 2016
Share
On September 8, 2016, Kang Stem Biotech Co., Ltd. closed the transaction.
Kang Stem Biotech Co., LTD is a Korea-based company mainly engaged in the development of pharmaceutical products. The Company's product portfolio consists of stem cell therapy products including Furestem-AD which used for treating atopic dermatitis, Furestem-RA which used for treating rheumatoid arthritis, Furestem-CD which used for treating crohnâs disease, stem cell conditioned medias which used as raw materials of cosmetics including umbilical cord blood-derived stem cell conditioned medias (USC-CMs) and others and stem cell culture medias including KSB-3 Complete Kit and others. The Company distributes its products within domestic market and to overseas markets.
Kang Stem Biotech Co., Ltd. announced that it has received KRW 30 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, LIG Investment & Securities Co., Ltd., Investment Arm, and other investors